|
| Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant) |
28 Apr 08, 22:30 |
|
| Merck & Co., Inc. today received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia ... |
| more |
|
